An interventional study of peripheral iridotomy in Glaucoma Eye and Angle Closure Glaucoma, sponsored by Isfahan University of Medical Sciences. Active, not recruiting at 1 site in Iran. Open to participants aged 24 Years and older. Per ClinicalTrials.gov, last updated 2025-09-26.
Sponsored by Isfahan University of Medical Sciences · Not applicable, Interventional, and Health services research
This study evaluates the effectiveness and safety of YAG laser peripheral iridotomy performed at two different locations (temporal and inferior) in patients with primary angle-closure glaucoma, a leading cause of blindness worldwide. Patients visiting the glaucoma clinic at Feiz Hospital who are candidates for peripheral iridotomy will participate. In each patient, one eye will receive a temporal iridotomy, and the other eye will receive an inferior iridotomy, with patients unaware of the location used in each eye. The study will measure outcomes such as laser power, intraocular pressure, visual symptoms, and complications over six months to determine which approach is more effective and safer.
91 studies on the registry are indexed under Glaucoma, Angle-Closure; 17 are open to participants now.
This study's planned enrollment of 150 is above the median of 57 across 58 interventional studies indexed under Glaucoma, Angle-Closure.
Browse Glaucoma, Angle-Closure studies →Isfahan University of Medical Sciences is the lead sponsor of 150 studies on the registry; 8 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Inclusion Criteria:Diagnosis of Primary Angle-Closure Glaucoma.
Adults (typically over 40 years old).
Ability to provide .
Narrow or closed anterior chamber angle (based on gonioscopy).
Intraocular pressure (IOP) controlled with medication but requiring surgery.
No previous iridotomy.
Exclusion Criteria:econdary glaucoma.
Active eye diseases (e.g., infection or inflammation).
Advanced cataracts or lens-related issues.
Severe visual impairment (e.g., less than 20/200 vision).
Uncontrolled systemic diseases (e.g., diabetes or cardiovascular disease).
Pregnancy or breastfeeding.
Previous eye surgery (except for minor procedures).
Inability to follow-up with scheduled visits.
-
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Other: peripheral iridotomy
This procedure involves using a neodymium-doped yttrium aluminum garnet (YAG) laser to create a small hole in the temporal region of the iris in one eye. It aims to relieve intraocular pressure in patients with primary angle-closure glaucoma by improving the flow of aqueous humor. The procedure is performed under local anesthesia in a clinical setting, with patients unaware of which eye receives this treatment. Outcomes, including laser power, intraocular pressure, visual symptoms, and complications, are monitored over six months.
adverse events
Surgical and postoperative complications (e.g., bleeding, infection, or changes in intraocular pressure).
Time frame: 1 day, 1 week, 1month
Plan to share: No
No publications or documents are linked to this record.
Started May 2025 (actual). Primary completion is estimated for Oct 2025, 5 months after the start.
Of 28 interventional studies with no phase under Glaucoma, Angle-Closure, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 43. This study's planned 5 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Isfahan University of Medical Sciences →